PulmOne Overview
PulmOne develops patient-friendly, hassle-free, and budget-conscious devices designed to accurately inform clinical decision making throughout the diagnosis, treatment, and monitoring of respiratory diseases. The company's MiniBox is a system for measuring lung volume and spirometry. It is a desktop device designed to provide an accurate assessment of lung volume based on normal tidal breathing and a short measurement time. The system does not rely on a plethysmograph or external gas source. PulmOne's MiniBox+ adds to the spirometry and LVM tests with a diffusing capacity (DLCO) module, providing a complete solution. The company has received FDA 510k clearance and a CE mark for its first product and started sales in several locations.
Cumulative Funding Raised Over Time ($)
$2.8MApr 2015
$6.8MDec 2021
$8.1MJun 2017
$12.1MMar 2022
$13.7MMay 2013
Latest News
growth-positive
Portable lung tests help patients breathe easier - Sponsored Content The Times of Israel
PulmOne, an Israeli startup, has developed MiniBox+, a compact device that allows pulmonary tests to be performed in clinics everywhere, reducing costs and speeding up diagnosis of lung diseases. The device, which has received FDA clearance, uses patented algorithms, machine-based learning, and an internal gasless measurement system to replace the traditional large, cumbersome equipment. PulmOne has signed agreements with a top US healthcare company and a leading medical technology distributor in China, and its revenues have more than doubled from 2020 to 2021. The company is currently raising funds on the OurCrowd platform.
CustomersPartnersInvestmentExpand
growth-positive
קרן רגנאר תשקיע 6.5 מיליון שקל בחברת המכשור הרפואי פאלם וואן כלכליסט
Regenar Fund is investing 6.5 million shekels in PalmOne, a company that develops and markets advanced medical equipment for lung function tests. PalmOne was aiming for an IPO at a value of $120 million, but business losses led to indications that it would not be able to raise the amount and the IPO was postponed. Instead, the company raised funds from Regenar at a value to be determined in the future. PalmOne has approval to market its products in the European Union since 2013, and from the American FDA since 2014.
Investment
growth-positive
פאלם וואן רוצה להנפיק בתל אביב לפי שווי של 120 מיליון דולר
Israeli medical equipment company Pulm One has received FDA and European Union approval to market its flagship device for lung function testing. The company has begun sales, including to medical centers in the US. The medical equipment market for lungs and breathing has seen increased demand due to the coronavirus, growing by 261% between 2019 and 2020. Pulm One is interested in issuing on the Tel Aviv Stock Exchange at a value of $120 million (420 million shekels).
Public Trading
growth-positive
PulmOne Now Offering FeNO by NIOX® with Its MiniBox+™ Complete Pulmonary Function Testing System
PulmOne USA Inc. has partnered with Circassia Pharmaceuticals to integrate the NIOX VERO fractional exhaled nitric oxide (FeNO) airway inflammation measurement system into PulmOnes MiniBox+. The integrated system will be offered to existing and new customers. The MiniBox+ is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients. The integration of the NIOX VERO asthma management system expands the testing capabilities of the MiniBox+, enabling physicians to detect and treat a wider range of respiratory disorders.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $13.71M |
| Last funding | $4M |
| Stage | A |
| Rounds | 5 |
| Investors | 2 |
Team Members
6
Employees: 51-200
Web & Social Links
| Website | www.pulm-one.com |
Locations
Ha-Melakha Street 14, Ra'anana, Israel
444 Madison Avenue, New York, NY, USA
Photos & Videos
3 item(s)
PulmOne Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical EquipmentCore Technology
Machinery & RoboticsTags (10)
hospitalspulmonarydiagnosticsmedical-devicesmonitoringrespiratorydoctorspatent-pendinghealthcare-providersclinicsGeographic Markets
EuropeUnited StatesJapanPulmOne Financials
$13.71M
Total funding
Undisclosed
Capital raised
$4M
Last funding
A
Funding stage
5
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$2.8MApr 2015
$6.8MDec 2021
$8.1MJun 2017
$12.1MMar 2022
$13.7MMay 2013
Private Equity Funding
Convertible Debt
Mar 2022
$4M
OurCrowd
Convertible Debt
Dec 2021
$4M
Alpha LTI (Lead)
,
OurCrowd
A Round
Jun 2017
$1.24M
OurCrowd
A Round
Apr 2015
$2.82M
OurCrowd (Lead)
A Round
May 2013
$1.65M
OurCrowd (Lead)
PulmOne Lifecycle
Cumulative Funding Raised Over Time
$2.8MApr 2015
$6.8MDec 2021
$8.1MJun 2017
$12.1MMar 2022
$13.7MMay 2013
All Events
Convertible Debt
Mar 2022
$4M
OurCrowd
Convertible Debt
Dec 2021
$4M
Alpha LTI (Lead)
,
OurCrowd
A Round
Jun 2017
$1.24M
OurCrowd
A Round
Apr 2015
$2.82M
OurCrowd (Lead)
A Round
May 2013
$1.65M
OurCrowd (Lead)
PulmOne News
4 articles
growth-positive
Portable lung tests help patients breathe easier - Sponsored Content The Times of Israel
PulmOne, an Israeli startup, has developed MiniBox+, a compact device that allows pulmonary tests to be performed in clinics everywhere, reducing costs and speeding up diagnosis of lung diseases. The device, which has received FDA clearance, uses patented algorithms, machine-based learning, and an internal gasless measurement system to replace the traditional large, cumbersome equipment. PulmOne has signed agreements with a top US healthcare company and a leading medical technology distributor in China, and its revenues have more than doubled from 2020 to 2021. The company is currently raising funds on the OurCrowd platform.
CustomersPartnersInvestmentExpand
growth-positive
קרן רגנאר תשקיע 6.5 מיליון שקל בחברת המכשור הרפואי פאלם וואן כלכליסט
Regenar Fund is investing 6.5 million shekels in PalmOne, a company that develops and markets advanced medical equipment for lung function tests. PalmOne was aiming for an IPO at a value of $120 million, but business losses led to indications that it would not be able to raise the amount and the IPO was postponed. Instead, the company raised funds from Regenar at a value to be determined in the future. PalmOne has approval to market its products in the European Union since 2013, and from the American FDA since 2014.
Investment
growth-positive
פאלם וואן רוצה להנפיק בתל אביב לפי שווי של 120 מיליון דולר
Israeli medical equipment company Pulm One has received FDA and European Union approval to market its flagship device for lung function testing. The company has begun sales, including to medical centers in the US. The medical equipment market for lungs and breathing has seen increased demand due to the coronavirus, growing by 261% between 2019 and 2020. Pulm One is interested in issuing on the Tel Aviv Stock Exchange at a value of $120 million (420 million shekels).
Public Trading
growth-positive
PulmOne Now Offering FeNO by NIOX® with Its MiniBox+™ Complete Pulmonary Function Testing System
PulmOne USA Inc. has partnered with Circassia Pharmaceuticals to integrate the NIOX VERO fractional exhaled nitric oxide (FeNO) airway inflammation measurement system into PulmOnes MiniBox+. The integrated system will be offered to existing and new customers. The MiniBox+ is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients. The integration of the NIOX VERO asthma management system expands the testing capabilities of the MiniBox+, enabling physicians to detect and treat a wider range of respiratory disorders.
PartnersCustomers
PulmOne Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 53 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
PulmOne Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 513812487 |
| Crunchbase | pulmone |
| Phone | +972775100938 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-10-27T00:00:00.000Z |
| Created | 2014-11-11T00:00:00.000Z |